Log In
Print this Print this

HuMax-TAC-ADC (ADCT-301)

  Manage Alerts
Collapse Summary General Information
Company ADC Therapeutics S.a.r.l.
DescriptionAntibody-drug conjugate (ADC) composed of HuMax-TAC, a human mAb targeting CD25, and a pyrrolobenzodiazepine (PBD) dimer toxin
Molecular Target Interleukin-2 (IL-2) receptor alpha chain (CD25)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today